Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis
New England Journal of Medicine · 18.12.2025 · 393 (24) · 2434-2446
DOI: 10.1056/nejmoa2502866 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 18.12.2025. Verfasst von David B Meya und 35 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Antitubercular Agents, Coinfection, Rifampin, Tuberculosis, Meningeal. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NINDS NIH HHS, Medical Research Council.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
- Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis.
- Centre for Global Health Research, Brighton and Sussex Medical School, Brighton, United Kingdom.
- Clinical Research Department, London School of Hygiene and Tropical Medicine, London.
- Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis.
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban.
ORCID-Profile: Fiona V Cresswell, Nathan C Bahr, David R Boulware
Förderung
- NIAID NIH HHS
- NINDS NIH HHS
- Medical Research Council
- Wellcome Trust
Zitieren
APA
Meya, D. B., Cresswell, F. V., Dai, B., Engen, N., Naidoo, K., Ganiem, A. R., Imran, D., Kabahubya, M., Lessells, R. J., Yunivita, V., Estiasari, R., Tugume, L., Hlabisa, B., Kurniawati, M. Y., Sagita, N., Kagimu, E., Maharani, K., Gakuru, J., Gaharu, M. N., …, & HARVEST Trial Team (2025). Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. New England Journal of Medicine, 393(24), 2434-2446. https://doi.org/10.1056/nejmoa2502866
Vancouver
Meya DB, Cresswell FV, Dai B, Engen N, Naidoo K, Ganiem AR, et al. Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. New England Journal of Medicine. 2025;393(24):2434-2446. doi:10.1056/nejmoa2502866
BibTeX
@article{Meya2025,
author = {Meya, David B and Cresswell, Fiona V and Dai, Biyue and Engen, Nicole and Naidoo, Kogieleum and Ganiem, Ahmad Rizal and Imran, Darma and Kabahubya, Mable and Lessells, Richard J and Yunivita, Vycke and Estiasari, Riwanti and Tugume, Lillian and Hlabisa, Bongeka and Kurniawati, Media Yuni and Sagita, Noveline and Kagimu, Enock and Maharani, Kartika and Gakuru, Jane and Gaharu, Maula N and Mugabi, Timothy and Kimuda, Sarah and Namombwe, Suzan and Te Brake, Lindsey and Aarnoutse, Rob and Svensson, Elin M and Bangdiwala, Ananta S and Namanda, Sylvia and Bahr, Nathan C and Musubire, Abdu K and Moosa, Mahomed Yunus Suleman and Hamers, Raph L and Marais, Suzaan and Boulware, David R and van Crevel, Reinout and Ruslami, Rovina and HARVEST Trial Team, HARVEST Trial Team},
title = {Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {24},
pages = {2434--2446},
doi = {10.1056/nejmoa2502866}
}
EUVIMED